Delcath Systems, Inc., was incorporated in Delaware in August 1988. The company is an interventional oncology company focused on the treatment of primary and liver metastatic cancers. The Company's lead product, HEPZATOTM KIT (" HEPZATO "melphalan for Injection/liver Delivery System), is a drug/device combination product approved by the U.S. Food and Drug Administration (FDA) on August 14, 2023 for the treatment of adult patients with uveal melanoma with unresectable liver metastases, Liver metastases in this patient affect less than 50% of the liver, and there is no extrahepatic disease, or extrahepatic disease is limited to bones, lymph nodes, and subcutaneous tissue.
